Attralus

**Attralus** is a **biopharmaceutical company** founded in **2019** and based in the **United States**. The company's mission, as stated in their slogan, is to create **transformative medicines for patients with systemic amyloidosis**. Attralus is currently in the clinical stage, focusing on developing **proprietary pan-amyloid removal (PAR) therapeutics**. These therapeutics are specifically designed to target and remove toxic amyloid in organs and tissues, with the potential to treat and reverse the disease in patients with all types and stages of systemic amyloidosis. The company recently received a significant investment of **$56.00M in Series B funding** on **06 February 2024**. The investors in this round included **Vivo Capital, Logos Capital, Sarissa Capital, VenBio Partners, Surveyor Capital, Bristol-Myers Squibb, and Alpha Wave Ventures**. This level of investment and the confidence shown by such reputable investors signifies a strong validation of Attralus' innovative approach and potential impact in the biopharmaceutical industry. With its focus on addressing a critical unmet medical need, Attralus has the potential to make a meaningful difference in the lives of patients with systemic amyloidosis.